Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma
暂无分享,去创建一个
Donna Rowen | Anna Morley | N. Maskell | D. Rowen | M. Versteegh | C. Hooper | A. Morley | Matthijs M Versteegh | David T Arnold | Clare E Hooper | Nicholas A Maskell | D. Arnold
[1] G. Torrance. Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.
[2] D. Feeny,et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. , 1996, Medical care.
[3] Jin-Hee Ahn,et al. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients , 2012, Health and Quality of Life Outcomes.
[4] Karl Claxton,et al. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. , 2016, Health economics.
[5] Donna Rowen,et al. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[6] Jeffrey A. Johnson,et al. A Comparison of EQ-5D Index Scores Derived from the US and UK Population-Based Scoring Functions , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[7] M. Neovius,et al. National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients , 2011, Annals of the rheumatic diseases.
[8] R. Prescott,et al. A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial. , 2007, Health technology assessment.
[9] R. Deyo,et al. Generic and Disease-Specific Measures in Assessing Health Status and Quality of Life , 1989, Medical care.
[10] J. Brazier,et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. , 2014, Health technology assessment.
[11] Benjamin M Craig,et al. Deriving a preference-based measure for cancer using the EORTC QLQ-C30. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[12] P. Sakthong,et al. Health and Quality of Life Outcomes , 2008 .
[13] Andrew Briggs,et al. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences , 2010, The European Journal of Health Economics.
[14] J. Brazier,et al. The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.
[15] J. Cairns,et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. , 2007, Health technology assessment.
[16] N. Thatcher,et al. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. , 2012, Lung cancer.
[17] G. Giaccone,et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Smala,et al. Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[19] M. Versteegh,et al. Condition-specific preference-based measures: benefit or burden? , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[20] Donna Rowen,et al. Mapping onto Eq-5 D for patients in poor health , 2010, Health and quality of life outcomes.
[21] Helen Dakin,et al. Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database , 2013, Health and Quality of Life Outcomes.
[22] Aki Tsuchiya,et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures , 2010, The European Journal of Health Economics.
[23] John Brazier,et al. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[24] P. Dolan,et al. Modeling valuations for EuroQol health states. , 1997, Medical care.
[25] J. Bond,et al. A pragmatic, randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer , 2004 .
[26] A. Haycox,et al. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. , 2007, Health Technology Assessment.
[27] M. Versteegh,et al. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[28] Nick Kontodimopoulos,et al. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[29] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[30] John Brazier,et al. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[31] F. Shepherd,et al. Derivation of Utility Values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[32] Hye-young Kang,et al. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients , 2012, Quality of Life Research.
[33] Jack Ishak,et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma , 2014, Health and Quality of Life Outcomes.
[34] M. van der Pol,et al. Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.